Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Synthetic heart graft patient reaches milestone:

This article was originally published in Clinica

Executive Summary

CardioTech International says that the first recipient of its investigational synthetic coronary artery bypass graft, CardioPass, has reached the one-year mark. The female patient, who had been considered a "no option" patient because she had no usable mammary artery, received the implant in Brazil in August 2003. She is currently leading a normal life, is asymptomatic and has no cardiac pain, said the Wilmington, Massachusetts firm. Her blood pressure and EKG are also both normal. In addition, two further patients who received the implant last year are also leading normal lives. CardioPass is designed to obviate the need for vessel harvesting surgery. CardioTech estimates the annual worldwide market for the synthetic graft will be in excess of $1bn.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT059337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel